Related Experiment Video

Updated: Oct 19, 2025

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis
07:32

Author Spotlight: Investigating Immune Cell Dynamics in the Tumor Microenvironment — Challenges and Innovations in Cancer Prognosis

Published on: April 12, 2024

1.6K

New prognostic factor for hepatitis B virus-related decompensated cirrhosis: Ratio of monocytes to HDL-cholesterol

Qianxia Wu1, Weilin Mao1

  • 1Department of Clinical Laboratory, College of Medicine, The First Affiliated Hospital, Zhejiang University, Hangzhou, China.

Journal of Clinical Laboratory Analysis
|September 21, 2021
PubMed

Insights

The monocyte-to-HDL-cholesterol ratio (MHR) is a significant predictor of short-term mortality in patients with Hepatitis B virus-related decompensated cirrhosis (HBV-DeCi). Elevated MHR indicates a higher risk of death in these patients.

Area of Science:

  • Hepatology
  • Clinical Medicine
  • Biomarker Research

Background:

  • Hepatitis B virus-related decompensated cirrhosis (HBV-DeCi) presents a significant clinical challenge due to its high mortality rate.
  • Predicting short-term outcomes in HBV-DeCi patients remains difficult, necessitating the identification of reliable prognostic markers.

Purpose of the Study:

  • To investigate the association between the monocyte-to-HDL-cholesterol ratio (MHR) and short-term prognosis in patients with HBV-DeCi.
  • To determine if MHR can serve as an independent predictor of mortality in this patient cohort.

Main Methods:

  • A cohort of 145 patients diagnosed with HBV-DeCi was analyzed.
  • Multivariate analysis was employed to identify independent predictors of 30-day mortality.
  • Receiver operating characteristic (ROC) analysis, including area under the curve (AUC), was used for validation.

Main Results:

  • A total of 20 (13.8%) patients died within 30 days of admission.
  • Non-survivors exhibited significantly higher MHR levels compared to survivors.
  • MHR was identified as an independent risk factor for mortality, with a significant predictive value (AUC = 0.825).

Conclusions:

  • Elevated MHR is strongly associated with an increased 30-day mortality rate in patients with HBV-DeCi.
  • MHR demonstrates potential as a valuable prognostic biomarker for assessing short-term outcomes in HBV-DeCi.
Abstract

Keywords:
decompensated cirrhosishepatitis B virusmonocyte-to-HDL-cholesterol ratiomortality predictor

More Related Videos

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

3.9K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.4K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
28
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
27
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
282